Cullinan Therapeutics (CGEM) Projected to Post Earnings on Wednesday

Cullinan Therapeutics (NASDAQ:CGEM) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Cullinan Therapeutics to post earnings of ($0.80) per share for the quarter.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Price Performance

Cullinan Therapeutics stock opened at $7.50 on Monday. Cullinan Therapeutics has a 12-month low of $6.85 and a 12-month high of $24.99. The stock has a market capitalization of $442.61 million, a P/E ratio of -2.64 and a beta of -0.07. The firm’s 50-day moving average is $8.01 and its two-hundred day moving average is $10.29.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. UBS Group decreased their price target on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, May 12th. Morgan Stanley reissued an “overweight” rating and issued a $35.00 target price (down from $38.00) on shares of Cullinan Therapeutics in a research report on Friday, March 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $33.00 target price on shares of Cullinan Therapeutics in a research report on Wednesday, April 16th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $32.00.

Insider Buying and Selling

In other Cullinan Therapeutics news, CEO Nadim Ahmed sold 12,529 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total transaction of $106,872.37. Following the transaction, the chief executive officer now directly owns 430,621 shares of the company’s stock, valued at $3,673,197.13. The trade was a 2.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey Alan Jones sold 4,895 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total transaction of $41,754.35. Following the transaction, the insider now directly owns 174,164 shares in the company, valued at approximately $1,485,618.92. This trade represents a 2.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.16% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cullinan Therapeutics stock. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 21,581 shares of the company’s stock, valued at approximately $163,000. 86.31% of the stock is owned by hedge funds and other institutional investors.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.